The treatment of malignant gliomas

Current Treatment Options in Neurology

Volumn 7, Issue 4, 2005, Pages 293-303

  Gilbert, Mark R ^a   Loghin, Monica ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; BB 251; CARBOPLATIN; CARMUSTINE; CILENGITIDE; CISPLATIN; CORTICOSTEROID DERIVATIVE; DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; FENRETINIDE; GANCICLOVIR; GEFITINIB; IMATINIB; IRINOTECAN; LENALIDOMIDE; LOMUSTINE; MARIMASTAT; MOLECULAR MARKER; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SEMAXANIB; TALAMPANEL; TEMOZOLOMIDE; TEMSIROLIMUS; THYMIDINE KINASE; TIPIFARNIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VIRUS VECTOR;

ADENOVIRUS; ALLELE; ANAPLASTIC CARCINOMA; ASTROCYTOMA; BRAIN TUMOR; BREAST CANCER; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; DNA METHYLATION; DRUG MECHANISM; GASTRITIS; GENE INACTIVATION; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; OLIGODENDROGLIOMA; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROMOTER REGION; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR CLASSIFICATION; VIRAL GENE DELIVERY SYSTEM;

EID: 22544485061     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-005-0039-6     Document Type: Review

References (67)

1. Legler JM, Ries LA, Smith MA, et al.: Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999, 91:1382-1390.
2. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics, 2002. CA Cancer J Clin 2002, 52:23-47.
3. Kleihues P, Cavenee WK, eds: Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press; 2000.
4. Andratschke N, Grosu AL, Molls M, Nieder C: Perspectives in the treatment of malignant gliomas in adults. Anticancer Res 2001, 21:3541-3550.
5. Barker II FG, Chang SM, Larson DA, et al.: Age and radiation response in glioblastoma multiforme. Neurosurgery 2001, 49:1288-1297; Discussion 1297-1298.
6. Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 2003, 30(Suppl 19):10-4.
7. Jeremic B, Milicic B, Grujicic D, et al.: Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol 2003, 129:477-484.
8. Jeremic B, Milicic B, Grujicic D, et al.: Clinical prognostic factors in patients with malignant glioma treated with combined modality approach. Am J Clin Oncol 2004, 27:195-204.
9. Lamborn KR, Chang SM, Prados MD: Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 2004, 6:227-235.
10. Wong ET, Hess KR, Gleason MJ, et al.: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572.
11. Curran Jr WJ, Scott CB, Horton J, et al.: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
12. Scott CB, Scarantino C, Urtasun R, et al.: Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys 1998, 40:51-55.
13. Bauman CS, Ino Y, Ueki K, et al.: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000, 48:825-830.
14. Ino Y, Zlatescu MC, Sasaki H, et al.: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000, 92:983-990.
15. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002, 20:2495-2499.
16. Esteller M, Garcia-Foncillas J, et al.: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000, 343:1350-1354.
17. Hegi ME, Diserens AC, Godard S, et al.: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004, 10:1871-1874.
18. Jaeckle KA, Eyre HJ, Townsend JJ, et al.: Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998, 16:3310-3315.
19. Hill C, Hunter SB, Brat DJ: Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 2003, 10:212-217.
20. Sansal I, Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004, 22:2954-2963.
21. Smith JS, Tachibana I, Passe SM, et al.: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001, 93:1246-1256.
22. Tanwar MK, Gilbert MR, Holland EC: Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002, 62:4364-4368.
23. Chamberlain MC, Kormanik PA: Practical guidelines for the treatment of malignant gliomas. West J Med 1998, 168:114-120.
24. Wen P, Toon TS, Black P: Clinical Imaging, and laboratory diagnosis of brain tumors. In: Laws E, Kaye A, editors. Brain Tumors. New York: Jones and Bartlett; 2001. p. 24-50.
25. Leeds NE, Kumar AJ, Jackson EF: Diagnostic Imaging. In Cancer in the Nervous System. Edited by Levin VA. Oxford: Oxford University Press; 2002:1-59.
26. Kucharczyk W, Henkelman RM: Visibility of calcium on MR and CT: can MR show calcium that Cr cannot? AJNR Am J Neuroradiol 1994, 15:1145-1148.
27. Barker II FG, Chang SM, Huhn SL, et al.: Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997, 80:936-941.
28. Graves EE, Nelson SJ, Vigneron DB, et al.: Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001, 22:613-624.
29. Kimura T, Sako K, Tohyama Y, et al.: Diagnosis and treatment of progressive space-occupying radiation necrosis following stereotactic radiosurgery for brain metastasis: value of proton magnetic resonance spectroscopy. Acta Neurochir (Wien) 2003, 145:557-64; discussion 564.
30. Lichy MP, Bachert P, Henze M, et al.: Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 2004, 46:126-129.
31. Nelson SJ, Huhn S, Vigneron DB, et al.: Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. J Magn Reson Imaging 1997, 7:1146-1152.
32. Rabinov JD, Lee PL, Barker FG, et al.: In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002, 225:871-879.
33. Chen CY, Lirng JF, Chan WP, Fang CL: Proton magnetic resonance spectroscopy-guided biopsy for cerebral glial tumors. J Formos Med Assoc 2004, 103:448-458.
34. Rock JP, Hearshen D, Scarpace L, et al.: Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51:912-919; discussion 919-920.
35. Jackson RJ, Fuller GN, Abi-Said D, et al.: Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncol 2001, 3:193-200.
36. Lacroix M, Abi-Said D, Fourney DR, et al.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198.
37. Pace A, Bove L, Innocenti P, et al.: Epilepsy and gliomas: incidence and treatment in 119 patients. J Exp Clin Cancer Res 1998, 17:479-482.
38. Moots PL, Maciunas RJ, Eisert DR, et al.: The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995, 52:717-24.
39. Glantz MJ, Cole BF, Forsyth PA, et al.: Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
40. Gilbert MR, Supko JG, Batchelor T, et al.: Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003, 9:2940-2949.
41. Grossman SA, Batara JF: Current management of glioblastoma multiforme. Semin Oncol 2004, 31:635-644.
42. Grossman SA, Hochberg F, Fisher J, et al.: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy. Cancer Chemother Pharmacol 1998, 42:118-226.
43. Ruff RL, Posner JB: Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983, 13:334-336.
44. Dhami MS, Bona RD, Calogero JA, Hellman RM: Venous thromboembolism and high grade gliomas. Thromb Haemost 1993, 70:393-396.
45. Altschuler E, Moosa H, Selker RG, Vertosick Jr Fr: The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990, 27:74-76; discussion 77.
46. Choucair AK, Silver P, Levin VA: Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism. J Neurosurg 1987, 66:357-358.
47. Fiveash JB, Spencer SA: Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J 2003, 9:222-229.
48. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
49. Stupp R, Mason WP, van den Bent M, et al.: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Proc ASCO 2004, 23:1.
50. Westphal M, Hilt DC, Bortey E, et al.: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 2003, 5:79-88.
51. Brem H, Piantadosi S, Burger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
52. Yung WK, Prados MD, Yaya-Tur R, et al.: Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762-2771.
53. Shaw EG, Tatter SB, Lesser GJ, et al.: Current controversies in the radiotherapeutic management of adult low-grade glioma. Semin Oncol 2004, 31:653-658.
54. Shaw EG, Wisoff JH: Prospective clinical trials of intracranial low-grade glioma in adults and children. Neuro-oncol 2003, 5:153-160.
55. Chinot O: Chemotherapy for the treatment of oligodendroglial tumors. Semin Oncol 2001, 28(Suppl 13):13-18.
56. Lesser GJ: Chemotherapy of low-grade gliomas. Semin Radiat Oncol 2001, 11:138-144.
57. Mason WP: Chemotherapy for low-grade gliomas. Forum (Genova) 2000, 10:95-104.
58. van den Bent MJ: Chemotherapy of oligodendroglial tumours: current developments. Forum (Genova) 2000, 10:108-118.
59. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al.: Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001, 7(4):839-45.
60. Levin VA: Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading. Neuro-oncol 1999, 1:69-80.
61. Wikstrand CJ, Cokgor I, Sampson JH, Bigner DD: Monoclonal antibody therapy of human gliomas: current status and future approaches. Cancer Metastasis Rev 1999, 18:451-464.
62. Kuan CT, Wikstrand CJ, Bigner DD: EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol 2000, 17:71-78.
63. Lang FF, Yung WK, Sawaya R, Tofilon PJ: Adenovirus-mediated p53 gene therapy for human gliomas. Neurosurgery 1999, 45:1093-1104.
64. Gomez-Manzano C, Balague C, Alemany R, et al.: A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 2004, 23:1821-1828.
65. Tremont-Lukats IW, Gilbert MR: Advances in molecular therapies in patients with brain tumors. Cancer Control 2003, 10:125-137.
66. Druker BJ: Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002, 1:31-36.
67. Mrugala MM, Kesari S, Ramakrishna N, Wen PY: Therapy for recurrent malignant glioma in adults. Expert Rev Anticancer Ther 2004, 4:759-782.